HiberCell, Inc. has acquired the Imprime PGG program from Biothera Pharmaceuticals, Inc.
This website will deactivate on August 31. To learn more visit HiberCell.com


Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences

EAGAN, MN — September 28, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s novel phase 2 cancer immunotherapy.  These presentations will provide data strengthening the scientific foundation for the use of Imprime PGG in combination with immune checkpoint inhibitors.  The high profile late-breaking session of the AACR-NCI- EORTC will feature initial...

Read More